Genzyme/Sanofi-Aventis
On February 16 2011, Genzyme Corporation (Nasdaq: GENZ) confirmed a definitive agreement to be acquired by Sanofi-aventis (NYSE: SNY) for $74.00 per share in cash, or approximately $20.1 billion, plus one Contingent Value Right.
The Contingent Value Right entitling the holder to receive additional cash payments if specified milestones related to Lemtrada™ are achieved over time or a milestone related to production volumes in 2011 for Cerezyme® and Fabrazyme® is achieved. The CVR will be publicly traded.
The transaction is expected to close early in the second quarter of 2011.
Evercore Partners and J.P. Morgan served as sanofi-aventis' lead financial advisors on the transaction, and Weil, Gotshal & Manges LLP served as its legal counsel. Credit Suisse and Goldman Sachs served as financial advisors to Genzyme. Ropes & Gray LLP served as Genzyme's legal counsel, while Wachtell, Lipton, Rosen & Katz served as legal counsel to Genzyme's independent directors.
The Contingent Value Right entitling the holder to receive additional cash payments if specified milestones related to Lemtrada™ are achieved over time or a milestone related to production volumes in 2011 for Cerezyme® and Fabrazyme® is achieved. The CVR will be publicly traded.
The transaction is expected to close early in the second quarter of 2011.
Evercore Partners and J.P. Morgan served as sanofi-aventis' lead financial advisors on the transaction, and Weil, Gotshal & Manges LLP served as its legal counsel. Credit Suisse and Goldman Sachs served as financial advisors to Genzyme. Ropes & Gray LLP served as Genzyme's legal counsel, while Wachtell, Lipton, Rosen & Katz served as legal counsel to Genzyme's independent directors.
View Older Stories
-
Geron Corp (GERN) Announces Appointment of Michelle Robertson as Executive Vice President, Chief Financial Officer and Treasurer,
-
Madrigal Pharma (MDGL) Appoints Bill Sibold as CEO
-
Invivyd (IVVD) Appoints William Duke as CFO
-
Catalent (CTLT) Announces Governance Enhancements and New Initiatives to Drive Value
-
Karuna Therapeutics (KRTX) Announces Leadership Appointments
-
Brainstorm Cell Therapeutics (BCLI) Appoints Bob Dagher as Chief Development Officer
-
Precision Optics Corporation, Inc. (POCI) Appoints Wayne Coll as CFO
-
Brainstorm Cell Therapeutics (BCLI) Appoints Kirk Taylor as EVP and Chief Medical Officer
-
Viridian Therapeutics (VRDN) Appoints Tony Casciano as Chief Commercial Officer
-
Innate Pharma (IPHA) Reports FY22, Provides Business Update
-
Enveric Biosciences (ENVB) Appoints Lynn Gallant as VP of Clinical Operations
-
Calyxt (CLXT) to Merge with Cibus
-
TFF Pharmaceuticals (TFFP) Appoints Zamaneh Mikhak as Chief Medical Officer
-
Biogen (BIIB) new CEO could be 'just what BIIB needs'
-
Stifel Reiterates Biogen (BIIB) at Buy with $299 PT Following CEO Appointment
-
Biogen (BIIB) Names Christopher Viehbacher President and Chief Executive Officer
-
Cara Therapeutics (CARA) Appoints Lisa von Moltke to its Board
-
Matinas BioPharma (MTNB) Announces Chairman Succession Plan
-
Geron Corp (GERN) Names John F. McDonald to Board
-
Sanofi (SNY) Genzyme's Xenpozyme Approved by FDA to Treat Acid Sphingomyelinase Deficiency
-
Magenta Therapeutics (MGTA) Appoints Michael Vasconcelles to its Board
-
Nuvalent Inc (NUVL) Promotes Darlene Noci to Chief Development Officer
-
Immunic Inc. (IMUX) Appoints Maria Tornsen to its Board
-
Forma Therapeutics Holdings (FMTX) Announces Executive Appoitments
-
Repligen (RGEN) Appoints Konstantin Konstantinov to its Board
-
Mereo BioPharma (MREO) Announces Appointment of Dr. Abdul Mullick to Board of Directors
-
Athira Pharma Inc. (ATHA) Appoints Michael A. Panzara to its Board
-
Dyne Therapeutics Inc. (DYN) Appoints Carlo Incerti to its Board
-
Rhythm Pharmaceuticals (RYTM) Announces Promotions within its Executive Leadership Team
-
NeuBase Therapeutics (NBSE) Appoints Eric J. Ende to its Board
-
Enveric Biosciences Inc. (ENVB) Appoints Bob Dagher as Chief Medical Officer
-
Immunogen (IMGN) Appoints Tracey L. McCain to its Board
-
Applied Genetic Technologies (AGTC) Appoints Abraham Scaria as Chief Science Officer
-
Precision BioSciences (DTIL) Appoints Sam Wadsworth to its Board
-
Inhibrx Inc. (INBX) Announces Key Executive Hires
-
Genprex (GNPX) Announces Appointments of Mark S. Berger, M.D. as CMO and Hemant Kumar, Ph.D. as Chief Manufacturing and Technology Officer
-
Matinas BioPharma (MTNB) Appoints Kathryn Penkus Corzo to its Board
-
Eloxx Pharmaceuticals (ELOX) Appoints Chief Medical Officer
-
PolarityTE (PTE) Names Richard Hague CEO, David Seaburg to Board, Ryan Mathis as Chief Medical Officer
-
Sanofi (SNY) announces FDA approves Nexviazyme, an important new treatment option for late-onset Pompe disease
-
Passage Bio (PASG) Appoints Chief Commercial Officer, Chief Financial Officer and Chief Medical Officer
-
Catalyst Pharmaceuticals (CPRX) Appoints Pharmaceutical Executive Molly Harper to its Board of Directors
-
Aeglea BioTherapeutics (AGLE) Appoints Marcio Souza to Board of Directors
-
Qualigen Therapeutics (QLGN) Appoints Tariq Arshad, MD, MBA as Chief Medical Officer
-
Timber Pharmaceuticals (TMBR) Announces Appointment of John Koconis as Chairman of the Board of Directors
-
Medicinova (MNOV) Receives Gene Therapy Milestone Payments
-
Translate Bio (TBIO) Appoints Dr. Rand Sutherland as President
-
Cyclo Therapeutics (CYTH) Appoints Gerald F. Cox, MD, PhD as Acting Chief Medical Officer
-
Magenta Therapeutics (MGTA) Highlights Recent Progress and Expected Timing of 2021 Milestones
-
DURECT Corp (DRRX) Announces Gail J. Maderis and Mohammad Azab to Board